[Cyproterone acetate: cardiovascular tolerance].
Cyproterone acetate, characterised by its antiandrogen and antigonadotrophin actions, is indicated in the treatment of advanced prostatic cancer. It can be used alone or in combination with surgical or chemical castration. This paper reviews the literature concerning the cardiovascular safety of this drug. Metabolic studies evaluating the impact of cyproterone acetate on lipids and certain clotting parameters indicate the absence of any harmful effects on these cardiovascular risk factors. The two trials conducted by the EORTC (30761 and 30 762) demonstrated that the cardiovascular safety of cyproterone acetate was better than that of diethylstilboestrol. Cardiovascular adverse effects were reported in less than 5% of cases. This figure was confirmed by a large number of published studies. A comparable incidence of cardiovascular complications was also observed in series of patients treated by orchidectomy, LHRH agonists and/or pure antiandrogens. It is difficult to formally demonstrate the responsibility of antihormonal treatment in this elderly population in which ischaemic heart disease and cerebral vascular accidents are frequent causes of death.